60 Degrees Pharmaceuticals (SXTP) Expected to Release Quarterly Earnings on Wednesday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.74) per share and revenue of $0.1850 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its earnings results on Friday, May 15th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.43 million. On average, analysts expect 60 Degrees Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

60 Degrees Pharmaceuticals Stock Up 1.2%

60 Degrees Pharmaceuticals stock opened at $1.25 on Wednesday. The firm has a market capitalization of $3.31 million, a P/E ratio of -0.14 and a beta of 2.54. The firm has a fifty day moving average of $1.52 and a 200-day moving average of $2.11. 60 Degrees Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $8.62.

Wall Street Analyst Weigh In

SXTP has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, June 24th. Ascendiant Capital Markets dropped their price target on shares of 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating for the company in a research note on Friday, May 22nd. Wall Street Zen downgraded shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 12th. Finally, HC Wainwright downgraded 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.85.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.